MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
NCT06150417
Recruiting
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called metastasis-directed radiotherapy (MDRT). The usual treatment for prostate cancer that has spread to other parts of the body is to give lifelong treatment with hormone therapy (also known as androgen deprivation therapy or ADT). Participants may also be given pros... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland, Ohio
Conditions: Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
Register for Updates
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
NCT02233751
Completed
Evaluation of pharmacokinetics of subcutaneous testosterone enanthate
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
01/18/2019
Locations: Medpace Clinical Pharmacology Unit, Cincinnati, Ohio
Conditions: Hypogonadism
Register for Updates
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT04947254
Recruiting
This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread to nearby tissue or lymph nodes (locally advanced). Androgen ablation therapy (also known as hormone therapy) lowers the levels of male hormones called androgens in the body. Androgens stimulate prostate cancer cells to grow. There are 2 types o... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
NCT05676463
Active Not Recruiting
This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time directly to diseased tissue, reducing damage to healthy tissue. Using MRI-guided radiation therapy on areas of the prostate and pelvic lymph nodes may shorten overall treatment tim... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Adaptions and Resiliency to Multi-Stressor OpeRations
NCT06455969
Recruiting
Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
08/18/2025
Locations: Neuromuscular Research Laboratory, Pittsburgh, Pennsylvania
Conditions: Musculoskeletal Injury, Hypogonadism
Register for Updates
Human Cerebral Blood Flow Regulation
NCT04265053
Completed
This study tests basic differences in how men and women control brain (cerebral) blood flow (CBF), at rest and under stress. The stress is low oxygen or high carbon dioxide. The investigators hypothesize that sex differences per se, plus sex hormone differences, drive different signals in blood vessels that change the way CBF is regulated. The investigators will test these mechanisms with medicine infusions during stress, and measure CBF using state-of-the-art MRI approaches. Research confoundin... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
08/14/2025
Locations: University of Wisconsin, Madison, Madison, Wisconsin
Conditions: Cerebral Arterial Diseases
Register for Updates
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT06075953
Recruiting
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the optio... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Berkeley Outpatient Center, Berkeley, California +14 locations
Conditions: Ductal Carcinoma in Situ
Register for Updates
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
NCT04267887
Active Not Recruiting
This phase II trial studies how well the combination of apalutamide, abiraterone acetate, and prednisone after chemotherapy work in treating patients that have received no prior treatment (treatment naive) for high risk prostate cancer that is sensitive to androgen deprivation therapy (castration sensitive) and has spread to other parts of the body (metastatic). This study also aims to understand the inheritance of prostate cancer. If a gene or genes that cause prostate cancer can be found, the... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
NCT06247267
Recruiting
It has been known that both estrogen and testosterone are the major sex steroids regulating bone metabolism and other physiological changes in both male and female, respectively. In postmenopausal women, osteoporosis is a major concern secondary to the lack of estrogen. These patients also experience a number of physiological changes that affect their life permanently to include hot flashes, irritability, difficulty concentrating, depression and mental confusion. In hypogonadal men, testosterone... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Hypogonadism, Gender Identity Dysphoria
Register for Updates
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
NCT05839730
Recruiting
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States. Data will be collected to evaluate whether pacing therapies can lead to improvements in exercise capacity and health status of subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: NCH Heart Institute, Naples, Florida +8 locations
Conditions: Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Register for Updates
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
NCT07092527
Not Yet Recruiting
This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
07/22/2025
Locations: University of California, San Diego, San Diego, California
Conditions: Transgenderism, Reproductive Issues
Register for Updates
Androgen Effects on the Reproductive Neuroendocrine Axis
NCT06450405
Terminated
This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
07/19/2025
Locations: University of California San Diego, San Diego, California
Conditions: Transgenderism, Reproductive Issues
Register for Updates